Salivary duct carcinoma (SDC) is an aggressive subtype of primary salivary gland
carcinoma, often with an advanced stage at presentation and high rates of metastasis and …

Background HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of
HER2 directed therapy have been reported in small studies. However, reliable estimates of …

Purpose Clinical evidence demonstrating the effectiveness of systemic therapy for advanced
salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the …

Background There is no standard first-line chemotherapy for recurrent/metastatic (RM) or
unresectable locally advanced (LA) salivary gland carcinoma (SGC). Patients and methods …

Purpose The correct classification of salivary gland pathologies is crucial for choosing a
treatment method and determining the prognosis. Better outcomes are now achievable …

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-
targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent …

Salivary duct carcinoma (SDC) is aggressive with limited therapeutic options. A subset of
SDC display human epidermal growth factor receptor 2 (HER2) protein overexpression by …

PURPOSE The activity of androgen-deprivation therapy (ADT) in androgen receptor–
positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few …

Although immune-checkpoint inhibitors (ICIs) are effective against various cancers, little is
known regarding their role in salivary gland carcinoma (SGC) treatment. Therefore, we …

Background Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland
cancer. Approximately half of SDC patients will develop recurrences or metastases …